HGH 191 Amino Acids: How 22 kDa Somatropin Differs from the 20 kDa Isoform
The familiar 191-amino-acid human growth hormone is the 22 kDa form; the natural 20 kDa isoform is a different splice product missing an internal 15-residue segment. The two proteins come from related transcripts of the GH1 gene and can bind the growth-hormone receptor, but they are not interchangeable identity labels. A material described as somatropin, 191 amino acids, should be evaluated against the full-length 22 kDa sequence and its own analytical record.
This distinction is especially important when search results mix native isoforms, recombinant somatropin, and short GH-derived peptides. The growth-hormone terminology guide separates these classes, while the HGH (Somatropin, 191 Amino Acid) page identifies the specific catalog entry.
Where does the 20 kDa form come from?
Molecular cloning work showed that the 20 kDa variant mRNA lacks 45 nucleotides corresponding to 15 amino acids present in the 22 kDa form. The deletion results from alternative splicing rather than trimming 15 residues from one end. The original cDNA study supports an internal sequence difference, not merely a difference in measured mass.
Later work mapped how alternative splice-site selection in the human GH transcript contributes to synthesis of the two isoforms. The splice-mechanism study describes the major 22 kDa and minor 20 kDa pituitary products. This biological background helps define the molecules, but it does not identify a separate vial without material-specific analysis.
| Record | Sequence relationship | Appropriate identity question | Common mistake |
|---|---|---|---|
| 22 kDa HGH | Full-length mature 191-amino-acid form | Does the material match the expected intact protein? | Treating nominal mass alone as proof |
| 20 kDa HGH | Alternative splice product with internal residues 32–46 absent | Is the internal deletion represented in sequence or peptide mapping? | Calling it a terminal fragment |
| AOD-9604 | Modified short peptide related to the C-terminal GH region | Does the exact short sequence and modification match? | Labeling it full-length HGH |
| hGH fragment 176–191 | Short C-terminal sequence description | Which numbering, termini, and modifications are present? | Assuming it is the same as AOD-9604 |
| Total GH immunoreactivity | Assay-dependent signal from recognized forms | Which isoforms does the antibody detect? | Equating signal with one pure molecular species |
Why molecular mass is not enough
“22 kDa” and “20 kDa” are conventional names, not complete specifications. Observed mass depends on sequence, disulfide state, adducts, charge assignment, calibration, and instrument method. Intact-mass analysis can support the expected molecular species, but peptide mapping or another sequence-sensitive method provides stronger evidence for an internal deletion.
Immunoassays create another boundary. An antibody may recognize an epitope shared by both isoforms or favor one form. A total GH result and a 22 kDa-specific result can therefore differ. Before comparing concentrations, check the assay’s cross-reactivity and calibration material.
Cell experiments have reported that both isoforms activate the GH receptor while producing nonidentical signaling kinetics and phosphorylation strength under the tested conditions. The comparative signaling study used defined engineered cell systems. It supports model-specific differences; it does not convert one isoform’s result into a claim about every GH material.
Keep full-length HGH separate from short fragments
The AOD-9604 and hGH fragment identity guide explains why an added N-terminal tyrosine changes a short-peptide record. That issue is separate from the 20 kDa splice deletion inside the full-length protein. Both examples show why residue count, sequence position, termini, and modification need to be written explicitly.
For practical documentation, record the stated sequence, amino-acid count, expected intact mass, disulfide connectivity, expression source if known, and analytical methods. Compare those fields with the exact lot in the COA library. The Growth Hormone Peptides collection provides navigation across related materials, while each entry keeps its own molecular identity.
Sequence coverage should also be reported carefully. Detecting a few shared tryptic peptides can support GH-family identity without distinguishing the 20 and 22 kDa forms. The decisive evidence needs to span the region containing the 15-residue difference or otherwise show the expected intact sequence. A method should state whether it can actually resolve that question.
Research limitations
The cited splicing papers establish naturally occurring transcript and protein relationships. The signaling paper used specific cell models and assay conditions. None of those sources verifies a commercial lot or proves equivalence among recombinant preparations. Intact mass, immunoreactivity, sequence coverage, aggregation, and content are separate quality questions. This article is an identity and evidence guide, not human-use instruction.
Frequently asked questions
Is 191-amino-acid HGH the 22 kDa form?
Yes. The standard mature 191-residue human growth hormone is conventionally called 22 kDa HGH.
Is the 20 kDa isoform a 171-amino-acid terminal fragment?
No. It is produced by alternative splicing and lacks an internal 15-residue segment corresponding to residues 32–46 of the 22 kDa sequence.
Can an immunoassay distinguish 20 and 22 kDa HGH?
Only if the assay is designed and validated for isoform selectivity. Many assays report broader immunoreactivity, so cross-reactivity must be checked.
Is AOD-9604 another name for 20 kDa HGH?
No. AOD-9604 is a short modified peptide related to the C-terminal GH region. It is not the natural 20 kDa splice isoform.